Literature DB >> 28872367

Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer.

D W Siemann1, D J Chaplin2, M R Horsman3.   

Abstract

Vascular targeted therapies (VTTs) are agents that target tumor vasculature and can be classified into two categories: those that inhibit angiogenesis and those that directly interfere with established tumor vasculature. Although both the anti-angiogenic agents (AAs) and the vascular disrupting agents (VDAs) target tumor vasculature, they differ in their mechanism of action and therapeutic application. Combining these two agents may realize the full potential of VTT and produce an effective therapeutic regimen. Here, we review AAs and VDAs (monotherapy and in combination with conventional therapies). We also discuss the rationale of combined VTT and its potential to treat cancer.

Entities:  

Keywords:  Anti-angiogenic agent; combretastatin A4-phosphate; vascular disrupting agent; vascular targeted therapy

Mesh:

Substances:

Year:  2017        PMID: 28872367     DOI: 10.1080/07357907.2017.1364745

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  15 in total

1.  Synthesis of dihydronaphthalene analogues inspired by combretastatin A-4 and their biological evaluation as anticancer agents.

Authors:  Casey J Maguire; Zhi Chen; Vani P Mocharla; Madhavi Sriram; Tracy E Strecker; Ernest Hamel; Heling Zhou; Ramona Lopez; Yifan Wang; Ralph P Mason; David J Chaplin; Mary Lynn Trawick; Kevin G Pinney
Journal:  Medchemcomm       Date:  2018-08-24       Impact factor: 3.597

Review 2.  Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2018-05       Impact factor: 9.546

3.  Role of vascular endothelial growth factor in radiotherapy resistance to esophageal squamous cell carcinoma.

Authors:  Xin Li; Xinyu Su; Chen Yan; Yuanyuan Ma; Heng Li; Jianhong Xia; Hongliang Li; Qian Jiang; Liqing Zhou; Zhengyun Zou
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-29       Impact factor: 4.553

Review 4.  Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in Tumors.

Authors:  Li Liu; Devin O'Kelly; Regan Schuetze; Graham Carlson; Heling Zhou; Mary Lynn Trawick; Kevin G Pinney; Ralph P Mason
Journal:  Molecules       Date:  2021-04-27       Impact factor: 4.411

Review 5.  Stromal cells in breast cancer as a potential therapeutic target.

Authors:  Samantha S Dykes; Veronica S Hughes; Jennifer M Wiggins; Henrietta O Fasanya; Mai Tanaka; Dietmar Siemann
Journal:  Oncotarget       Date:  2018-05-04

Review 6.  Angiogenesis: Managing the Culprits behind Tumorigenesis and Metastasis.

Authors:  Ashwaq Hamid Salem Yehya; Muhammad Asif; Sven Hans Petersen; Ayappa V Subramaniam; Koji Kono; Amin Malik Shah Abdul Majid; Chern Ein Oon
Journal:  Medicina (Kaunas)       Date:  2018-03-25       Impact factor: 2.430

7.  Tumors Resistant to Checkpoint Inhibitors Can Become Sensitive after Treatment with Vascular Disrupting Agents.

Authors:  Michael R Horsman; Thomas R Wittenborn; Patricia S Nielsen; Pernille B Elming
Journal:  Int J Mol Sci       Date:  2020-07-06       Impact factor: 5.923

8.  Real-World Data on Apatinib Efficacy - Results of a Retrospective Study in Metastatic Breast Cancer Patients Pretreated With Multiline Treatment.

Authors:  Zhaoyun Liu; Jing Shan; Qian Yu; Xinzhao Wang; Xiang Song; Fukai Wang; Chao Li; Zhiyong Yu; Jinming Yu
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

Review 9.  Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies.

Authors:  Letizia Procaccio; Vera Damuzzo; Francesca Di Sarra; Alberto Russi; Federica Todino; Vincenzo Dadduzio; Francesca Bergamo; Alessandra Anna Prete; Sara Lonardi; Hans Prenen; Angelo Claudio Palozzo; Fotios Loupakis
Journal:  Drug Saf       Date:  2019-02       Impact factor: 5.228

10.  Heterogeneous Expression of Proangiogenic and Coagulation Proteins in Gliomas of Different Histopathological Grade.

Authors:  Marek Z Wojtukiewicz; Marta Mysliwiec; Elwira Matuszewska; Stanislaw Sulkowski; Lech Zimnoch; Barbara Politynska; Anna M Wojtukiewicz; Stephanie C Tucker; Kenneth V Honn
Journal:  Pathol Oncol Res       Date:  2021-03-31       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.